Wedge Capital Management L L P NC Acquires 73,714 Shares of Hologic, Inc. (NASDAQ:HOLX)

Share on StockTwits

Wedge Capital Management L L P NC lifted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 10.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 779,568 shares of the medical equipment provider’s stock after acquiring an additional 73,714 shares during the period. Wedge Capital Management L L P NC’s holdings in Hologic were worth $40,701,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the company. Price T Rowe Associates Inc. MD lifted its stake in Hologic by 0.3% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 42,197,163 shares of the medical equipment provider’s stock valued at $2,026,308,000 after purchasing an additional 116,925 shares during the last quarter. BlackRock Inc. increased its position in shares of Hologic by 0.5% during the 2nd quarter. BlackRock Inc. now owns 18,609,553 shares of the medical equipment provider’s stock valued at $893,630,000 after purchasing an additional 95,737 shares during the last quarter. Parnassus Investments CA raised its stake in shares of Hologic by 1.9% during the 3rd quarter. Parnassus Investments CA now owns 15,825,872 shares of the medical equipment provider’s stock worth $799,048,000 after purchasing an additional 300,090 shares during the period. Nuveen Asset Management LLC raised its stake in shares of Hologic by 72,308.7% during the 2nd quarter. Nuveen Asset Management LLC now owns 5,304,658 shares of the medical equipment provider’s stock worth $254,730,000 after purchasing an additional 5,297,332 shares during the period. Finally, D. E. Shaw & Co. Inc. boosted its holdings in shares of Hologic by 17.2% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 1,521,300 shares of the medical equipment provider’s stock worth $73,053,000 after buying an additional 223,217 shares during the last quarter. 94.06% of the stock is owned by institutional investors.

In related news, CEO Stephen P. Macmillan sold 194,396 shares of Hologic stock in a transaction on Monday, November 11th. The shares were sold at an average price of $45.91, for a total value of $8,924,720.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Benjamin Jordan Cohn sold 4,379 shares of the business’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $52.74, for a total transaction of $230,948.46. Insiders sold 251,453 shares of company stock worth $11,871,295 in the last quarter. 0.90% of the stock is currently owned by company insiders.

Shares of NASDAQ HOLX opened at $53.75 on Thursday. The company has a debt-to-equity ratio of 1.32, a quick ratio of 1.26 and a current ratio of 1.68. Hologic, Inc. has a fifty-two week low of $42.61 and a fifty-two week high of $54.24. The stock has a market cap of $14.35 billion, a PE ratio of 22.12, a price-to-earnings-growth ratio of 2.35 and a beta of 0.76. The stock has a fifty day moving average of $52.43 and a 200-day moving average of $49.79.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, November 6th. The medical equipment provider reported $0.65 EPS for the quarter, hitting the consensus estimate of $0.65. The business had revenue of $865.80 million during the quarter, compared to the consensus estimate of $846.54 million. Hologic had a positive return on equity of 29.67% and a negative net margin of 1.19%. The firm’s revenue was up 6.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.58 EPS. On average, sell-side analysts predict that Hologic, Inc. will post 2.62 EPS for the current year.

A number of analysts recently issued reports on the stock. Bank of America upgraded shares of Hologic from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $54.00 to $59.00 in a report on Thursday, September 26th. Needham & Company LLC boosted their target price on shares of Hologic from $57.00 to $62.00 and gave the company a “buy” rating in a research note on Monday. Barclays increased their target price on shares of Hologic from $50.00 to $51.00 and gave the company an “equal weight” rating in a research report on Monday. William Blair restated a “buy” rating on shares of Hologic in a research note on Thursday, November 21st. Finally, Citigroup began coverage on shares of Hologic in a report on Monday, January 6th. They issued a “buy” rating and a $60.00 price target on the stock. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $55.38.

Hologic Company Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Story: Pattern Day Trader – What is the PDT Rule?

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.